This trial is studying pembrolizumab and sunitinib malate to treat thymic cancer.
1 Primary · 3 Secondary · Reporting Duration: Up to 24 months
Experimental Treatment
40 Total Participants · 1 Treatment Group
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: